Table 1 RADAR study cohort demographic information.

From: Assessment of a dried blood spot C-reactive protein method to identify disease flares in rheumatoid arthritis patients

 

Flare (1) n = 67

No flare (2) n = 25

Total n = 100

t-test P value (1) vs. (2)

Female, n (%)

49

(73%)

13

(52%)

68

(68%)

–

Age, mean (SD), years

56.3

(11.7)

59.0

(13)

57.2

(12.6)

ns

Disease Duration, mean (SD), years

6.0

(3.8)

6.5

(4.5)

6.0

(3.9)

ns

Erythrocyte Sedimentation Rate, mean (SD), mm per hr (T0)

16.1

(15.8)

12.1

(15.2)

15.5

(15.5)

ns

Patient Assessed Pain (T0)

55.4

(28.)

32.2

(28.1)

47.3

(30.2)

 < 0.01

Patient global assessment of disease activity (PGA) (T0)

58.2

(26.1)

39.3

(28.3)

50.8

(30.2)

 < 0.01

C-reactive Protein (T0), mean (SD), mg/L

8.0

(10.7)

7.7

(11.9)

7.9

(0.8)

ns

Change in CRP (T6–T0)

13.1

(88.8)

1.0

(10.8)

9.3

(73.7)

ns

Disease Activity Score in 28 joints (DAS28-ESR), mean (SD) (T0)

3.9

(1.5)

3.1

(1.4)

3.6

(1.5)

0.025

DAS28-ESR (T6–T0)

0.4

(1.2)

0.2

(1.1)

0.4

(1.2)

ns

  1. Patients are grouped depending on disease flare reported during the 6-week follow up period; 8 of the 100 participants did not provide their flare status. Baseline mean values are indicated by (T0), whereas changes over the period of the study are indicated by (T6–T0) values. Patient assessed pain and disease activity were recorded by participants at T0 and T6 on a 0–100 visual analogue scale. Two sample parametric, two tailed t tests were performed for baseline DAS28, baseline CRP, patient assessed pain and disease activity. Two sample non parametric, one tailed t tests were performed for change in DAS28 and change in CRP data.
  2. SD standard deviation, ns no significant difference.
Back to article page